Please login to the form below

Not currently logged in
Email:
Password:

S-A collaborates to develop antibodies

S-A has entered into a global collaboration agreement to develop an antibody against an antigen present on the surface of carcinoma cells

Sanofi-aventis (S-A) has entered into a global collaboration agreement with Micromet to develop an antibody against an antigen present on the surface of carcinoma cells.

Under the terms of the agreement, Micromet will take responsibility for discovery, research and development of the antibody through the phase I clinical trial process, under the supervision of a Joint Steering Committee. Further development and worldwide commercialisation of the antibody will be sanofi-aventis' responsibility.

Upon signing the agreement, S-A will make an upfront payment of €8m to Micromet. Additionally, Micromet will be eligible for up to €312m in milestone and royalty payments.

"Micromet's BiTE antibodies represent a promising new approach to treating cancer," declared Marc Cluzel, senior vice-resident R&D, sanofi-aventis. "We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future."

29th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics